Our pipeline of high-value
product opportunities
product opportunities
LIFE-001:
The ultimate pipeline-in-a-product
LIFE-001 is advancing for the treatment of multiple immune-mediated disorders and organ transplant rejection.
LIFE-001 is a precision-engineered, controlled-release, organ-sparing, immunophilin-independent calcineurin inhibitor being developed for multiple immune-mediated disease indications and organ transplant rejection.
With a previously unprecedented structure and mechanism of action, LIFE-001 has the potential to become a field-dominating universal T cell immunosuppressant with applicability across multiple indications and significant advantages over legacy calcineurin inhibitors and most if not all other classes of immunosuppressants.
LIFE-001 has demonstrated compelling efficacy in preclinical models of ulcerative colitis and Crohn’s disease and has shown unequivocally improved safety over legacy calcineurin inhibitors.
LIFE-001 is currently being evaluated in a first-in-human Phase 1 clinical trial.
Drug Discovery & Development Alliance with
LifeMine and GlaxoSmithKline (GSK) entered a drug discovery and development alliance, the first such agreement in genomic drug discovery from fungi, to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas.